PTJ
RPRX icon

Paul Tudor Jones’s Royalty Pharma RPRX Stock Holding History

Paul Tudor Jones’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-45,200
Closed -$2.17M – 4177
2026
Q1 		$2.17M Buy
+45,200
New +$1.98M ﹤0.01% 1787

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's RPRX Position: Q2 2026 in Review

Paul Tudor Jones reduced its Royalty Pharma (RPRX) stake by 9.1% in Q2 2026, selling an estimated $3.17M and leaving 610,736 shares worth $34.2M. The position accounts for 0.05% of the portfolio, ranked #296.

Paul Tudor Jones first reported a position in RPRX in Q2 2023 and has held it in 13 quarters since. The position peaked at $35.7M in Q4 2025. 640 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Paul Tudor Jones held 610,736 shares of Royalty Pharma worth $34.2M as of Q2 2026.
  • Paul Tudor Jones sold 60,944 Royalty Pharma shares in Q2 2026, an estimated $3.17M.
  • Royalty Pharma made up 0.05% of Paul Tudor Jones's portfolio in Q2 2026, its #296 holding.
  • Paul Tudor Jones first reported a position in Royalty Pharma in Q2 2023 and has held it in 13 quarters since.
  • Paul Tudor Jones's Royalty Pharma position peaked at $35.7M in Q4 2025.
  • 640 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.